Company name Registered office Vedim Ltd. ............................................................ 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Viking Trading Co. Ltd. ....................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Zhuhai Schwarz Pharma Company Ltd ................ Block A. Changsa Industrial Zone. Qianshan District, Zhuhai, Guangdong Province, 519070 China A11250830/2.25/23 Oct 2009 116 Percentage Voting rights at shareholders’ meeting 100 100 75
PART XI: DESCRIPTION OF THE SHARES AND ARTICLES OF ASSOCIATION 1. FORMATION, LEGAL AND COMMERCIAL NAME, FINANCIAL YEAR <strong>UCB</strong>’s legal predecessor, Societe Industrielle de la Cellulose, was founded on 19 May 1925. As part of a merger the name of the company changed to Union Chimique-Chemische Bedrijven on 27 November 1961, and changed again to <strong>UCB</strong> S.A. on 15 December 1970. <strong>UCB</strong> is currently registered as a public limited liability company organised under Belgian law (société anonyme/naamloze vennootschap) registered in the Belgian Crossroads Bank for Enterprises under 0403 053 608. The registered offices of <strong>UCB</strong> S.A. are located at 60 Allée de la Recherche, 1070 Brussels, Belgium. <strong>UCB</strong>’s legal name is “<strong>UCB</strong> S.A.”. <strong>UCB</strong>’s principal place of business is at 60 Allée de la Recherche, 1070 Brussels, Belgium, telephone number +32 2 559 9264 (Investor Relations). The duration of <strong>UCB</strong>, as set forth in article 4 of the Articles, is unlimited. <strong>UCB</strong>’s financial year corresponds to the calendar year. Following the end of each financial year, the Board approves the draft of the financial statements to be submitted for approval to the ordinary General Meeting. The ordinary General Meeting is to be held each year on the last Thursday of April. 2. CORPORATE PURPOSE According to article 3 of the Articles, the purpose of the company is to hold and manage direct or indirect shareholdings in other companies having a purpose directly or indirectly related to research, development, industrial or commercial activities, focused mainly but not exclusively on the pharmaceutical industry. The company can provide support services for third parties, in particular for companies in which the company has a direct or indirect interest. More generally it can undertake any commercial, industrial, financial, property, or real estate operations both in Belgium and elsewhere, which may be directly or indirectly related to the above purposes, including, without being limited to, the financing of the companies in which it has an interest by way of loans, guarantees, grants of securities or in any other manner. 3. SHARE CAPITAL AND SHARES At the time of publication of this Prospectus, the share capital of the Issuer amounted to €550,095,156 divided into 183,365,052 Ordinary Shares. The Ordinary Shares do not have a nominal value. The Ordinary Shares are admitted for listing and trading on Eurolist by Euronext Brussels. For information on the Issuer’s authority to issue the Bonds, see Part XV, “General Information”. 4. FORM AND TRANSFERABILITY OF THE ORDINARY SHARES The Ordinary Shares can take the form of registered shares or dematerialised shares. All Ordinary Shares are fully paid-up and freely transferable. A11250830/2.25/23 Oct 2009 117 A4 – 14.2.1 A4 – 5.1.1 A4 – 5.1.2 A4 – 5.1.3 A4 – 5.1.4 A4 – 14.2 A4 – 14.2.1